TMD

Titan Amends Amalgamation Agreement with Conavi Medical Inc. and Announces Extension of 2023 Annual General and Special Meeting

Retrieved on: 
Mercredi, mai 29, 2024
Toronto Stock Exchange, Special, Bank statement, AGM, Amalgamation, Concurrency, TSX, TMD

TORONTO, Ontario, May 29, 2024 (GLOBE NEWSWIRE) -- Titan Medical Inc. (“Titan”) (TSX: TMD; OTC: TMDIF) is pleased to announce that it has entered into an amending agreement dated May 28, 2024 (the “Amending Agreement”), in respect of the previously announced amalgamation agreement dated March 17, 2024 (the “Amalgamation Agreement”) among Conavi Medical Inc. (“Conavi”), 1000824255 Ontario Inc. (a wholly-owned subsidiary of Titan) and Titan, to result in the merger of Conavi and Titan (the “Proposed Transaction”).

Key Points: 
  • TORONTO, Ontario, May 29, 2024 (GLOBE NEWSWIRE) -- Titan Medical Inc. (“Titan”) (TSX: TMD; OTC: TMDIF) is pleased to announce that it has entered into an amending agreement dated May 28, 2024 (the “Amending Agreement”), in respect of the previously announced amalgamation agreement dated March 17, 2024 (the “Amalgamation Agreement”) among Conavi Medical Inc. (“Conavi”), 1000824255 Ontario Inc. (a wholly-owned subsidiary of Titan) and Titan, to result in the merger of Conavi and Titan (the “Proposed Transaction”).
  • In addition, Titan announces that the Toronto Stock Exchange (“TSX”) has granted Titan an extension to hold its Annual General and Special Meeting of Shareholders (the “AGM”) on or before July 31, 2024.
  • As consideration for Titan entering into the Amending Agreement and agreeing to extend the various dates set forth therein, Conavi has agreed to advance $150,000 to Titan as a deposit for   direct and incremental expenses Titan may incur as a result of the extension to a maximum of $150,000.
  • Titan intends to schedule a date for the AGM as soon as practicable and to provide shareholders with the requisite notice of meeting and record date associated therewith.

Titan Provides Update on Planned Merger with Conavi

Retrieved on: 
Vendredi, mai 17, 2024
Titan, Completion, See, Transaction, Circular, TSX, TMD, Bank

TORONTO, Ontario, May 17, 2024 (GLOBE NEWSWIRE) -- Titan Medical Inc. (“Titan”) (TSX: TMD; OTC: TMDIF) is providing an update on its planned merger with Conavi Medical Inc. (“Conavi”) pursuant to the definitive amalgamation agreement (the “Amalgamation Agreement”) dated March 17, 2024 (the “Transaction”), as previously announced on March 18, 2024 and April 22, 2024.

Key Points: 
  • TORONTO, Ontario, May 17, 2024 (GLOBE NEWSWIRE) -- Titan Medical Inc. (“Titan”) (TSX: TMD; OTC: TMDIF) is providing an update on its planned merger with Conavi Medical Inc. (“Conavi”) pursuant to the definitive amalgamation agreement (the “Amalgamation Agreement”) dated March 17, 2024 (the “Transaction”), as previously announced on March 18, 2024 and April 22, 2024.
  • Titan and Conavi are both working on satisfying the closing conditions outlined in the Amalgamation Agreement, which includes:
    Completion and submission to the TSXV of the joint management information circular (the “Circular”) and related documents.
  • Please see the Amalgamation Agreement, a copy of which is available on SEDAR at sedarplus.ca.
  • For full details on the risks and uncertainties affecting the Company, please refer to the Company’s Annual Information Form (See section entitled “Risk Factors”) for the year ended December 31, 2023, a copy of which is available on SEDAR+ at sedarplus.ca.

Titan Provides Update on Planned Merger with Conavi

Retrieved on: 
Lundi, avril 22, 2024
Completion, TMD, TSX, Toronto Stock Exchange, Transaction, TSX Venture Exchange

TORONTO, Ontario, April 22, 2024 (GLOBE NEWSWIRE) --  Titan Medical Inc. (“Titan”) (TSX: TMD; OTC: TMDIF) is pleased to provide this update on its planned merger with Conavi Medical Inc. (“Conavi”) as previously announced on March 18, 2024 (the “Transaction”).

Key Points: 
  • TORONTO, Ontario, April 22, 2024 (GLOBE NEWSWIRE) --  Titan Medical Inc. (“Titan”) (TSX: TMD; OTC: TMDIF) is pleased to provide this update on its planned merger with Conavi Medical Inc. (“Conavi”) as previously announced on March 18, 2024 (the “Transaction”).
  • As previously announced, Titan has entered into a definitive amalgamation agreement (the “Amalgamation Agreement”) dated March 17, 2024 with Conavi Medical Inc. (“Conavi”) providing for the combination of the companies in an all-stock transaction.
  • The combined company will focus on continuing to commercialize Conavi’s Novasight Hybrid™ System designed to guide common minimally invasive coronary procedures.
  • Titan and Conavi continue to work towards the satisfaction of the conditions to completion of the Transaction set forth in the Amalgamation Agreement, including the parties’ work currently underway in respect of the following:
    Preparation of submissions to the TSXV in connection with Titan’s planned applications for the listing of its common shares on the TSX Venture Exchange (the “TSXV”) and their delisting from the Toronto Stock Exchange (the “TSX”) and for TSXV approval of the Transaction;
    Completion of Titan’s management information circular (the “Titan Circular”) and related documents in connection with Titan’s annual and special meeting at which Titan’s shareholders will be asked to approve the Transaction and other related matters; and
    Conavi’s efforts in connection with a concurrent financing of subscription receipts (convertible into Conavi Shares immediately prior to completion of the Transaction), the terms of which will be announced at a later date (the “Concurrent Financing”), for minimum gross proceeds of US$15 million up to a maximum of US$20 million.

The San Francisco Peninsula Convention and Visitors Bureau Appoints Maggie Lang as Chief Sales and Marketing Officer

Retrieved on: 
Mercredi, avril 17, 2024
Travel, Lang, TMD, DMO, SFP, Marketing, San Francisco Peninsula, Knowledge, Sales, Tourism

BURLINGAME, Calif., April 17, 2024 /PRNewswire/ -- The San Francisco Peninsula (TSFP), the regional destination marketing organization (DMO) that represents 14 dynamic communities on the peninsula south of San Francisco, has announced a crucial new development to its multiyear brand transformation plan: the addition of Maggie Lang as the new Chief Marketing and Sales Officer. An industry-seasoned professional, Lang brings over 30 years of sales and marketing experience in travel, hospitality, and retail to the San Francisco Peninsula, and she has spearheaded the development of numerous sophisticated and successful global platforms, brands and programs.

Key Points: 
  • In this new senior leadership position at TSFP, Lang leads the Sales and Marketing team and agency network to support the organization's transformation, evolution and continued success.
  • Lang plays a key role in the development of the dynamic destination's new sales and marketing campaigns dedicated to attracting business and leisure travelers to the region.
  • We eagerly anticipate an exceptionally bright future with Maggie at the helm of our Sales and Marketing team."
  • Editor's Note: Maggie Lang's headshot is available to download here (credit: The San Francisco Peninsula).

Titan Settles Contractual Dispute with Contract Manufacturer

Retrieved on: 
Lundi, avril 1, 2024
TMD, TSX, Contractor

TORONTO, Ontario, April 01, 2024 (GLOBE NEWSWIRE) -- Titan Medical Inc. (“Titan”) (TSX: TMD; OTC: TMDIF) announces that it has entered into a settlement agreement with a contract manufacturer (“Contractor”).

Key Points: 
  • TORONTO, Ontario, April 01, 2024 (GLOBE NEWSWIRE) -- Titan Medical Inc. (“Titan”) (TSX: TMD; OTC: TMDIF) announces that it has entered into a settlement agreement with a contract manufacturer (“Contractor”).
  • Titan has reached a settlement agreement in connection with a dispute with the Contractor.
  • Under the terms of the settlement, Titan has agreed to pay the Contractor an aggregate of US$2 million, with the final payment installment to be made on or before June 24, 2024.
  • Upon receipt of the full US$2 million, the Contractor will deliver the outstanding material, inventory, and works-in-progress to Titan.

Titan Medical Reports Fiscal Year 2023 Results

Retrieved on: 
Vendredi, mars 29, 2024
Titan, Indian stock exchange, Research, MNP, Development, TSX Venture Exchange, G&A, Medtronic, MD, MBA, TMD, TSX, Intuition, Transaction, MNP LLP

TORONTO, Ontario, March 29, 2024 (GLOBE NEWSWIRE) -- Titan Medical Inc. (“Titan” or the “Company”) (TSX: TMD; OTC: TMDIF), today reported financial results for the fiscal year ended December 31, 2023.

Key Points: 
  • TORONTO, Ontario, March 29, 2024 (GLOBE NEWSWIRE) -- Titan Medical Inc. (“Titan” or the “Company”) (TSX: TMD; OTC: TMDIF), today reported financial results for the fiscal year ended December 31, 2023.
  • On August 21, 2023, the Company announced a licensing agreement with Auris Health, Inc., a Johnson & Johnson MedTech Company.
  • On October 18, 2023, the Company announced it had changed its auditor from BDO Canada LLP to MNP LLP.
  • As of December 31, 2023, Titan had cash of $7.5 million, compared to $3.3 million on December 31, 2022.

Titan Announces Q&A Session with Shareholders

Retrieved on: 
Mercredi, mars 20, 2024
Interim, TMD, TSX, Q&A

TORONTO, Ontario, March 20, 2024 (GLOBE NEWSWIRE) -- Titan Medical Inc. (“Titan”) (TSX: TMD; OTC: TMDIF) announces that management will host a webcast Q&A session on March 27, 2024 at 1:00 p.m.

Key Points: 
  • TORONTO, Ontario, March 20, 2024 (GLOBE NEWSWIRE) -- Titan Medical Inc. (“Titan”) (TSX: TMD; OTC: TMDIF) announces that management will host a webcast Q&A session on March 27, 2024 at 1:00 p.m.
  • Titan will provide prepared remarks followed by a Q&A session.
  • Paul Cataford, Interim President and CEO and Chien Huang, Chief Financial Officer will attend the session on behalf of Titan.
  • Shareholders are invited to submit questions in advance of the Q&A session to [email protected] .

Titan Announces Merger Agreement with Conavi

Retrieved on: 
Lundi, mars 18, 2024
TSX Venture Exchange, Agreement, Health Canada, IP, OCT, RAS, Chairperson, Toronto Stock Exchange, Consolidation, Combined, Reverse, Concurrency, Food, TMD, TSX, Transaction, IVUS, Security (finance)

TORONTO, Ontario, March 18, 2024 (GLOBE NEWSWIRE) -- Titan Medical Inc. (“Titan”) (TSX: TMD; OTC: TMDIF) is pleased to announce that it has entered into a definitive amalgamation agreement (the “Amalgamation Agreement”) dated March 17, 2024 with Conavi Medical Inc. (“Conavi”) to combine the companies in an all-stock transaction.

Key Points: 
  • TORONTO, Ontario, March 18, 2024 (GLOBE NEWSWIRE) -- Titan Medical Inc. (“Titan”) (TSX: TMD; OTC: TMDIF) is pleased to announce that it has entered into a definitive amalgamation agreement (the “Amalgamation Agreement”) dated March 17, 2024 with Conavi Medical Inc. (“Conavi”) to combine the companies in an all-stock transaction.
  • Under the terms of the Agreement, Titan will acquire all of the issued and outstanding shares of Conavi (the “Conavi Shares”) and in exchange Conavi shareholders will be issued common shares of Titan (the “Combined Entity Shares”).
  • Throughout 2023, it was made clear to Titan that a merger with another RAS company was not a viable option and Titan broadened its search for a merger partner beyond RAS.
  • The Titan Board is unanimous in its decision to execute the Amalgamation Agreement and to recommend this Transaction to its shareholders (the “Titan Shareholders”).

Titan Medical to Report Year-End 2023 Financial Results on March 29, 2024

Retrieved on: 
Lundi, mars 4, 2024
Titan, TSX, TMD

TORONTO, Ontario, March 04, 2024 (GLOBE NEWSWIRE) -- Titan Medical Inc. (“Titan” or the “Company”) (TSX: TMD; OTC: TMDIF), announced today that the Company plans to issue its year-end 2023 financial results after the market closing on March 29, 2024.

Key Points: 

TORONTO, Ontario, March 04, 2024 (GLOBE NEWSWIRE) -- Titan Medical Inc. (“Titan” or the “Company”) (TSX: TMD; OTC: TMDIF), announced today that the Company plans to issue its year-end 2023 financial results after the market closing on March 29, 2024.

Titan Medical Announces Benchmark Electronics, Inc. Purported to Terminate Agreement

Retrieved on: 
Vendredi, décembre 1, 2023
Titan, TSX, TMD, Electronics

TORONTO, Ontario, Dec. 01, 2023 (GLOBE NEWSWIRE) -- Titan Medical Inc. (“Titan” or the “Company”) (TSX: TMD; OTC: TMDIF), announced today that Benchmark Electronics, Inc., the company engaged by Titan under a manufacturing and supply agreement for the manufacture of Titan’s Enos Surgical System, has purported to terminate the agreement.

Key Points: 
  • TORONTO, Ontario, Dec. 01, 2023 (GLOBE NEWSWIRE) -- Titan Medical Inc. (“Titan” or the “Company”) (TSX: TMD; OTC: TMDIF), announced today that Benchmark Electronics, Inc., the company engaged by Titan under a manufacturing and supply agreement for the manufacture of Titan’s Enos Surgical System, has purported to terminate the agreement.
  • Titan did not receive delivery from Benchmark of manufactured Enos Surgical System units and disputes that Benchmark has grounds for the termination.
  • Titan has rejected Benchmark’s allegation that Titan breached the agreement.